Theta Burst Stimulation for Gambling Disorder

NCT ID: NCT05872750

Last Updated: 2023-05-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-17
• Study Completion Date: 2026-06-30

Brief Summary

The goal of this clinical trial is to investigate the efficacy of theta burst stimulation in individuals with gambling disorder. The main goal is to compare the severity of gambling problems following 2 weeks of intervention between active group and sham group. Participants will be randomized into active and sham group. The severity of gambling problems are assessed by self-reported questionaires.

Detailed Description

Gambling disorder, formerly known as pathological gambling, is a gambling behavior that causes significant function impairment in personal, social, occupational domains. Currently there is no pharmacological treatment for gambling disorder and it is urgent to develop innovative treatment modalities. Image studies have found a link between prefrontal circuit dysfunction and behavioral disinhibition, which supports the use of non-invasive brain stimulation as a potential treatment for gambling disorder. In this study, 75 patients with gambling disorder will be randomly assigned in a 2:1 ratio to the intervention group (50 patients) and the control group (25 patients) on double-blind basis. The study duration is 2 weeks, with 10 sessions of 20 minutes each. The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area, while the control group will receive sham stimulation. The Chinese version of the Problem Gambling Severity Index (PGSI), the Gambling Symptom Assessment Scale (G-SAS), and the Visual Analogue Scale (VAS) for craving will be administered at week 0, 2, 4, 8, and the change in gambling severity between the two groups will be compared by repeated measures ANOVA.

Conditions

Gambling Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Active arm

The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area

Group Type: EXPERIMENTAL

theta burst stimulation

Intervention Type: DEVICE

Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)

Sham arm

the control group will receive sham stimulation

Group Type: SHAM_COMPARATOR

sham stimulation

Intervention Type: DEVICE

sham stimulation

Interventions

theta burst stimulation

Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)

Intervention Type: DEVICE

sham stimulation

sham stimulation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. age between 18 and 65 years;

2. fulfilling at least 4 of the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of gambling disorder for at least 12-month assessed by the Structured Clinical Interview

Exclusion Criteria

1. Inability to provide informed consent or comprehend the study procedure;

2. A major psychiatric illness that required chronic psychotropic medication or inpatient treatment, including schizophrenia spectrum disorder, bipolar spectrum disorder, and major depressive disorder with psychotic features.

3. A current DSM-5 diagnosis of substance use disorder except nicotine use disorder or the use of one to two low-potency benzodiazepine tablets for sleep impairment;

4. Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic medications, or with cochlear implants.

5. Unstable medical illness, including malignancy, uncontrolled diabetes mellitus, unstable cardiac disease or recent myocardial infarction, or cerebrovascular or cardiovascular risk factors that require intensive medical management

6. On medications known to lower seizure threshold (e.g., TCA, bupropion, clozapine)

7. Implants controlled by physiological signals, including pacemaker, implantable cardioverter defibrillator, cochlear implant.

8. Metallic objects in the head, including stenting, suture.

9. Elevated risk of seizure due to traumatic brain history, seizure history, and head trauma, intracranial lesion, and alcohol or benzodiazepines withdrawal syndrome, stimulant intoxication.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taipei City Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hu-Ming Chang

Role: PRINCIPAL_INVESTIGATOR

Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan

Locations

Taipei City Hospital

Taipei, Taipei CITY, Taiwan

Site Status: RECRUITING

Countries

Taiwan

Central Contacts

Hu-Ming Chang

Role: CONTACT

DAU66@tpech.gov.tw

0978052951

Facility Contacts

Hu-Ming Chang

Role: primary

DAU66@tpech.gov.tw

0978052951

Other Identifiers

TCHIRB-11104005

Identifier Type: -

Identifier Source: org_study_id